ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Stock Information for ContraFect Corporation
Loading
Please wait while we load your information from QuoteMedia.